PARP inhibitor · small molecule

veliparib

4 active trials across 4 of our biomarkers, targeting PARP. Not approved for any biomarker on marked.bio yet.

Also known as ABT-888.

Counts only trials that select patients by one of the biomarkers on marked.bio, not every trial of this drug.

Biomarkers

Biomarker	Active trials	All trials	Furthest active phase
BRCA1/2 mutation	3	22	Phase 2
IDH1/2 mutation	1	1	Phase 2
EGFR exon 19 deletion / L858R	0	1	–
MSI-H / dMMR	0	1	–

Trials

4 of 25 trials shown

Veliparib, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed Malignant Glioma Without H3 K27M or BRAFV600 Mutations

Active, not recruiting Phase 2 Children's Oncology Group Started 2018Primary completion 2023-03 NCT03581292

temozolomideveliparib

Stratum 2 (IDH mutant): Patients must be \>= 3 years of age and =\< 25 years of age at the time of enrollment

IDH1/2 mutationAnaplastic Astrocytoma, Glioblastoma, Malignant Glioma
Gemcitabine Hydrochloride and Cisplatin With or Without Veliparib or Veliparib Alone in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer

Active, not recruiting Phase 2 National Cancer Institute (NCI) Started 2012Primary completion 2024-12 NCT01585805

cisplatingemcitabineveliparib

…Gemcitabine, Cisplatin +/- Veliparib in Patients With Pancreas Adenocarcinoma and a Known BRCA/ PALB2 Mutation (Part I) and a Phase II Single Arm Study of Single-Agent Veliparib in Previously Treated …

BRCA1/2 mutationLocally Advanced Pancreatic Adenocarcinoma, Metastatic Pancreatic Adenocarcinoma, Stage III Pancreatic Cancer AJCC v8, Stage IV Pancreatic Cancer AJCC v8
Veliparib and Dinaciclib in Treating Patients With Advanced Solid Tumors

Active, not recruiting Phase 1 National Cancer Institute (NCI) Started 2011Primary completion 2023-03 NCT01434316

Dinaciclibveliparib

Patients enrolling in the BRCA-deficient cohorts must have a documented BRCA1 or BRCA2 germline mutation

BRCA1/2 mutationAdvanced Malignant Solid Neoplasm
Veliparib and Carboplatin in Treating Patients With HER2-Negative Metastatic Breast Cancer

Active, not recruiting Phase 1 National Cancer Institute (NCI) Started 2010Primary completion 2024-09 NCT01251874

carboplatinveliparib

HER negative with a known germline BRCA1/2 mutation

BRCA1/2 mutationRecurrent Breast Carcinoma, Stage IIIB Breast Cancer AJCC v7, Stage IIIC Breast Cancer AJCC v7, Stage IV Breast Cancer AJCC v6 and v7
Response to PARP Inhibitor Predicted by the RAD51 Assay

Withdrawn Phase 2 University Medical Center Groningen Started 2019 NCT03044795

veliparib

…e (≥ 6 months since last platinum containing therapy) high grade serous ovarian cancer or BRCA1/2 mutated (non-)breast and (non-)ovarian cancer.

BRCA1/2 mutationCancer
Combination of Carboplatin, Eribulin and Veliparib in Stage IV Cancer Patients

Withdrawn Phase 2 The University of Texas Health Science Center at San Antonio Started 2017 NCT03032614

carboplatineribulinveliparib

Patients must have BRCA1/2 deleterious mutations, PTEN deficiency, or cancer with a high HRD score as assessed by Myriad's assay

BRCA1/2 mutationBreast Cancer Stage IV, Ovarian Cancer, BRCA1 Mutation, BRCA2 Mutation
Cisplatin With or Without Veliparib in Treating Patients With Recurrent or Metastatic Triple-Negative and/or BRCA Mutation-Associated Breast Cancer With or Without Brain Metastases

Completed Phase 2 National Cancer Institute (NCI) Started 2016 NCT02595905

cisplatinveliparib

BRCA mutation: previously confirmed deleterious breast cancer 1, early onset (BRCA1) or breast cancer 2…

BRCA1/2 mutationMetastatic BRCA Hereditary Breast Carcinoma, Metastatic Breast Carcinoma, Metastatic Malignant Neoplasm in the Brain, Metastatic Triple-Negative Breast Carcinoma
A Clinical Study Conducted in Multiple Centers Comparing Veliparib in Combination With Carboplatin and Paclitaxel Versus a Placebo in Combination With Carboplatin and Paclitaxel in Patients With Advanced Non-small Cell Lung Cancer

Completed Phase 2 AbbVie Started 2012 NCT01560104

veliparibcarboplatinpaclitaxel

Subjects with a known epidermal growth factor receptor (EGFR) mutation of exon 19 deletion or L858R mutation in exon 21. (Subjects with wild type epidermal growth factor receptor (…

EGFR exon 19 deletion / L858RNon-Small -Cell Lung Cancer
Veliparib in Treating Patients With Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Completed Phase 2 National Cancer Institute (NCI) Started 2012 NCT01540565

veliparib

… epithelial ovarian, fallopian tube, or primary peritoneal carcinoma AND carry a germline mutation in BRCA1 or BRCA2 (confirmation required via Myriad test report)

BRCA1/2 mutationBRCA1 Mutation Carrier, BRCA2 Mutation Carrier, Ovarian Epithelial Tumor, Recurrent Fallopian Tube Carcinoma
Study Evaluating Efficacy And Tolerability Of Veliparib in Combination With Temozolomide (TMZ) or In Combination With Carboplatin and Paclitaxel Versus Placebo in Participants With Breast Cancer Gene (BRCA)1 and BRCA2 Mutation and Metastatic Breast Cancer

Completed Phase 2 AbbVie Started 2012 NCT01506609

veliparibcarboplatintemozolomidepaclitaxel

…n With Carboplatin and Paclitaxel Versus Placebo in Participants With Breast Cancer Gene (BRCA)1 and BRCA2 Mutation and Metastatic Breast Cancer

BRCA1/2 mutationMetastatic Breast Cancer
Phase II ABT-888 With Cyclophosphamide

Completed Phase 2 National Cancer Institute (NCI) Started 2011 NCT01306032

veliparibcyclophosphamide

BRCA-positive ovarian cancer (documented deleterious BRCA1/2 mutation or a BRCAPRO score of greater tha…

BRCA1/2 mutationOvarian Cancer, Primary Peritoneal Cancer, Serous Carcinoma Cancer, Triple-Negative Breast Cancer
Veliparib Monotherapy for Relapsed Ovarian Cancer With BRCA Mutation

Completed Phase 1/2 Vejle Hospital Started 2011 NCT01472783

veliparib

Patients with known germline BRCA1/2 mutations

BRCA1/2 mutationRecurrent, Epithelial Ovarian Cancer
Veliparib With or Without Carboplatin in Treating Patients With Stage III or IV Breast Cancer

Completed Phase 2 National Cancer Institute (NCI) Started 2010 NCT01149083

carboplatinveliparib

Patients must have a known deleterious BRCA mutation confirmed by report from a Clinical Laboratory Improvement Amendments (CLIA) certified la…

BRCA1/2 mutationAnatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Locally Advanced Breast Carcinoma, Metastatic Breast Carcinoma
ABT-888 and Temozolomide for Metastatic Breast Cancer and BRCA1/2 Breast Cancer

Completed Phase 2 Steven J Isakoff, MD, PhD Started 2009 NCT01009788

veliparibtemozolomide

Patients must have known deleterious mutation of BRCA1/2

BRCA1/2 mutationBreast Cancer, Metastatic Breast Cancer, BRCA1 Gene Mutation, brca2 Gene Mutation
Phase I/Ib Study of Nivolumab & Veliparib in Patients With Advanced Solid Tumors & Lymphoma

Completed Phase 1 Northwestern University Started 2017 NCT03061188

nivolumab FDA EUveliparib

…Hodgkin's lymphoma, Merkel cell carcinoma, and high-frequency microsatellite instability (MSI-H) colorectal cancer

MSI-H / dMMRAdvanced Solid Neoplasm, Aggressive Non-Hodgkin Lymphoma, Recurrent Solid Neoplasm, Refractory Mantle Cell Lymphoma
A Phase 1 Study of Single Agent Veliparib in Japanese Subjects With Advanced Solid Tumors

Completed Phase 1 AbbVie Started 2014 NCT02210663

veliparib

Subjects with BRCA-mutated breast cancer who have received prior chemotherapy with anthracycline and/or taxanes

BRCA1/2 mutationAdvanced Solid Tumors
A Study Evaluating Veliparib as a Single Agent or in Combination With Chemotherapy in Subjects With Solid Tumors

Completed Phase 1 AbbVie Started 2013 NCT02033551

veliparibcarboplatinpaclitaxelFOLFIRI

For Veliparib monotherapy (must have tumor with defects in DNA repair mechanisms (BRCA mutation or high grade ovarian cancer or solid tumors for combination therapy.

BRCA1/2 mutationBreast Cancer, Ovarian Cancer, Colon Cancer, Lung Cancer
A Study to Evaluate the Safety, Pharmacokinetics and Oral Bio Availability of Veliparib in Subjects With Solid Tumors

Completed Phase 1 AbbVie Started 2013 NCT01853306

veliparib

Subjects must also 1) have a documented BRCA1 or BRCA2 mutation that is considered to be deleterious by the investigator, OR 2) have high grade serous ov…

BRCA1/2 mutationOncology, BRCA Mutated, High Grade Serous Ovarian Cancer, BRCA Mutated Breast Cancer
Veliparib, Oxaliplatin, and Capecitabine in Treating Patients With Advanced Solid Tumors

Terminated Phase 1 National Cancer Institute (NCI) Started 2010 NCT01233505

veliparibcapecitabineoxaliplatin

BRCA1/2 mutation and a BRCA-related malignancy

BRCA1/2 mutationAdenocarcinoma of the Pancreas, Adenocarcinoma of the Stomach, BRCA1 Mutation Carrier, BRCA2 Mutation Carrier
ABT-888 and Gemcitabine Hydrochloride in Treating Patients With Advanced Solid Tumors

Completed Phase 1 National Cancer Institute (NCI) Started 2010 NCT01154426

gemcitabineveliparib

… mutation undergo screening with the BRCAPRO program to assess the likelihood of having a BRCA mutation

BRCA1/2 mutationAdult Solid Neoplasm, BRCA1 Mutation Carrier, BRCA2 Mutation Carrier
Veliparib, Cisplatin, and Vinorelbine Ditartrate in Treating Patients With Recurrent and/or Metastatic Breast Cancer

Completed Phase 1 University of Washington Started 2010 NCT01104259

veliparibcisplatinvinorelbine

Confirmed BRCA1 or BRCA2 mutation associated breast cancer

BRCA1/2 mutationEstrogen Receptor-negative Breast Cancer, HER2-negative Breast Cancer, Hereditary Breast/Ovarian Cancer - BRCA1, Hereditary Breast/Ovarian Cancer - BRCA2
Veliparib in Treating Patients With Malignant Solid Tumors That Do Not Respond to Previous Therapy

Completed Phase 1 National Cancer Institute (NCI) Started 2009 NCT00892736

veliparib

Have a documented BRCA1/2 mutation and a BRCA related malignancy (primarily breast or ovarian cancers, but also may include …

BRCA1/2 mutationBasal-Like Breast Carcinoma, BRCA1 Mutation Carrier, BRCA2 Mutation Carrier, Breast Carcinoma
Veliparib and Irinotecan Hydrochloride in Treating Patients With Cancer That Is Metastatic or Cannot Be Removed by Surgery

Completed Phase 1 National Cancer Institute (NCI) Started 2008 NCT00576654

irinotecanveliparib

…portion of the study will consist of two cohorts: those patients who are triple-negative, BRCA-mutant positive and those patients who have triple-negative, non-BRCA mutated breast cancer

BRCA1/2 mutationAdvanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm, Triple-Negative Breast Carcinoma, Unresectable Solid Neoplasm
Veliparib, Carboplatin, and Paclitaxel in Treating Patients With Advanced Solid Cancer

Completed Phase 1 National Cancer Institute (NCI) Started 2007 NCT00535119

carboplatinpaclitaxelveliparib

Patients enrolled in stratum II of the study must have BRCA1/2 mutation (added 04/07/09)

BRCA1/2 mutationAdult Solid Neoplasm, BRCA1 Mutation Carrier, BRCA2 Mutation Carrier, Hereditary Breast and Ovarian Cancer Syndrome
Pilot Study of Veliparib (ABT-888) and Lapatinib (Tykerb) in Patients With Metastatic, Triple Negative Breast Cancer

Completed No phase University of Alabama at Birmingham Started 2014 NCT02158507

velipariblapatinib

Patients with BRCA 1 or 2 mutations will not be included.

BRCA1/2 mutationMetastatic Triple Negative Breast Cancer